The combination of oral anticoagulation (OAC) and aspirin was the antithrombotic treatment initially adopted after coronary stenting (PCI-S). Although dual antiplatelet therapy with aspirin and a thienopyridine subsequently proved safer and more effective, OAC and aspirin combination is still used in patients with an indication for long-term OAC undergoing PCI-S. The absolute (AR) and relative (RR) risk of cardiac events and hemorrhagic/vascular complications of OAC and aspirin versus antiplatelet therapy were evaluated in a meta-analysis of four historical clinical trials. In 2,436 patients, the RR of a 30-day primary composite endpoint of death, myocardial infarction and the need for revascularization was significantly reduced by antiplatelet therapy (RR 0.41; 95% CI 0.25–0.69), whereas the RR of stent thrombosis (RR 0.26; 95% CI 0.06–1.14) and major bleeding (RR 0.36; 95% CI 0.14–1.02) was not statistically different. The 30-day AR of death, myocardial infarction, need for revascularization, major bleedings and vascular complications with OAC and aspirin were 0.65, 3.8, 4.2, 6.4 and 6.6%, respectively. In conclusion, due to the low AR of adverse events, the combination of OAC and aspirin appears an acceptable treatment after PCI-S in patients in whom long-term OAC is deemed mandatory.

Keywords:
Coronary angioplasty, Coronary stent, Oral anticoagulants, Ticlopidine, Aspirin, Antiplatelets
1.
Schömig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084–1089.
2.
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665–1671.
3.
Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1996;98:1597–1603.
4.
Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998;98:2126–2132.
5.
Cosmi B, Rubboli A, Castelvetri C, Milandri M: Ticlopidine versus oral anticoagulation after coronary stenting (Cochrane review). Cochrane Database Syst Rev 2001;4:CD002133.
6.
Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G: Antithrombotic treatment after coronary artery stenting in patients on chronic oral anticoagulation: an international survey of current clinical practice. Ital Heart J 2004;5:851–856.
7.
Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, Berger PB: Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147:463–467.
8.
Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G: Antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary artery stenting: safety and efficacy data from a single center. Ital Heart J 2004;5:919–925.
9.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trias: is blinding necessary? Control Clin Trials 1996;17:1–12.
10.
Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408–412.
11.
Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46.
12.
Landis RJ, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977;33:159–174.
13.
Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220S–227S.
14.
Hull RD, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P: Warfarin sodium versus low-dose heparin for the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855–858.
15.
Hirsh J, Lee A: How we diagnose and treat deep vein thrombosis. Blood 2002;99:3102–3110.
16.
Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG: Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S–193S.
17.
Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194S–206S.
18.
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–3488.
19.
Nasser T, Mohleri EI, Wilensky R, Hathaway D: Peripheral vascular complications following coronary interventional procedures. Clin Cardiol 1995;18:609–614.
20.
Waksman R, King SB 3rd, Douglas JS, Shen Y, Ewing H, Mueller L, Ghazzal ZM, Weintraub WS: Predictors of groin complications after balloon and new device coronary intervention. Am J Cardiol 1995;75:886–889.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.